当前位置: X-MOL 学术CNS Neurosci. Ther. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
B3GNT5 is a novel marker correlated with stem-like phenotype and poor clinical outcome in human gliomas.
CNS Neuroscience & Therapeutics ( IF 5.5 ) Pub Date : 2020-07-16 , DOI: 10.1111/cns.13439
Hang Yeon Jeong 1 , Seo-Young Park 1 , Hyun-Jin Kim 1 , Seungju Moon 1 , Seongsoo Lee 2 , Seung Ho Lee 3 , Sung-Hak Kim 1, 2
Affiliation  

Glioblastoma multiforme (GBM) is the most lethal tumor with a median patient survival of 14 to 15 months. Glioma stem cells (GSCs) play a critical role in tumor initiation and therapeutic resistance in GBM. B3GNT5 has been suggested as the key glycosyltransferase in the biosynthesis of the (neo‐) lacto series of glycosphingolipid. In this study, we evaluated the B3GNT5 expression in GSCs as well as the correlation with clinical data in GBM.

中文翻译:

B3GNT5 是一种新型标记物,与干细胞样表型和人类神经胶质瘤的不良临床结果相关。

多形性胶质母细胞瘤( GBM) 是最致命的肿瘤,患者的中位生存期为 14 至 15 个月。胶质瘤干细胞 (GSC) 在 GBM 的肿瘤起始和治疗抵抗中起着关键作用。B3GNT5 被认为是(新)乳系列鞘糖脂生物合成中的关键糖基转移酶。在这项研究中,我们评估了GSC 中 B3GNT5 的表达以及与 GBM 中临床数据的相关性。
更新日期:2020-07-16
down
wechat
bug